Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.
Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy (FAP): Updated Safety and Efficacy Najat Khan, Ph.D ., Chief R&D and Chief Commercial Officer and incoming CEO and ...
Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present ...
The transparency gap isn’t just anecdotal. Stanford’s Foundation Model Transparency Index initially scored leading developers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback